LIPOSOMAL IRINOTECAN IN COMBINATION WITH OXALIPLATIN, 5-FLUOROURACIL AND LEUCOVORIN (NALIRIFOX) FOR THE FIRST-LINE TREATMENT OF ADULT PATIENTS WITH METASTATIC ADENOCARCINOMA OF THE PANCREAS. A BUDGET IMPACT ANALYSIS IN GREECE
Author(s)
VASILIKI CHOTZAGIANNOGLOU, MBA, MSc, PharmD1, Andriani Angelopoulou, PhD2, Eleana Solakidou, PhD(c)1, Charalampos Tzanetakos, MSc3, George Gourzoulidis, PhD2.
1SERVIER HELLAS PHARMACEUTICALS Ltd, Athens, Greece, 2Health Through Evidence, Athens, Greece, 3Health Through Evidece, Athens, Greece.
1SERVIER HELLAS PHARMACEUTICALS Ltd, Athens, Greece, 2Health Through Evidence, Athens, Greece, 3Health Through Evidece, Athens, Greece.
OBJECTIVES: To estimate the budget impact from the introduction of Liposomal Irinotecan (Onivyde®) in combination with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) for the first-line treatment (FLT) of adult patients with metastatic adenocarcinoma of the pancreas (mPDAC) in Greece.
METHODS: A budget impact model was developed from a public payer perspective over a 3-year time horizon to assess the financial consequences of NALIRIFOX adoption. Based on local clinical practice, the treatment options considered in the model included FOLFIRINOX, gemcitabine, gemcitabine plus oxaliplatin, and gemcitabine plus nab-paclitaxel (GemNabPac), with GemNabPac representing the most widely prescribed first-line regimen in Greece. The model compared market share scenarios with and without NALIRIFOX, applying reimbursed treatment costs to the eligible patient population. Patient numbers were estimated from published literature, and projected uptake of NALIRIFOX was informed by Servier Hellas. Drug acquisition costs were considered in the analysis and were retrieved from the Greek Ministry of Health (€,2025). The model measured outcome was incremental budget impact from the introduction of NALIRIFOX as a treatment option in patient with mPDAC.
RESULTS: With the introduction of NALIRIFOX, 3-year total expenditure was estimated at €24,893,555 compared with €14,093,277 without NALIRIFOX in the market. Market share for NALIRIFOX was projected to increase from 18% in year 1 to 30% in year 3. The inclusion of NALIRIFOX resulted in an average additional cost of €2,387 per patient per year. Across the 3-year horizon, the average annual budget impact was €3,618,093.
CONCLUSIONS: mPDAC is associated with poor prognosis and limited treatment options, creating a high unmet medical need. By improving survival and quality of life, NALIRIFOX represents an important advance for patients and a valuable option for clinicians managing this challenging disease. The introduction of NALIRIFOX provides clinically meaningful benefits with a manageable budget impact for the Greek public payer.
METHODS: A budget impact model was developed from a public payer perspective over a 3-year time horizon to assess the financial consequences of NALIRIFOX adoption. Based on local clinical practice, the treatment options considered in the model included FOLFIRINOX, gemcitabine, gemcitabine plus oxaliplatin, and gemcitabine plus nab-paclitaxel (GemNabPac), with GemNabPac representing the most widely prescribed first-line regimen in Greece. The model compared market share scenarios with and without NALIRIFOX, applying reimbursed treatment costs to the eligible patient population. Patient numbers were estimated from published literature, and projected uptake of NALIRIFOX was informed by Servier Hellas. Drug acquisition costs were considered in the analysis and were retrieved from the Greek Ministry of Health (€,2025). The model measured outcome was incremental budget impact from the introduction of NALIRIFOX as a treatment option in patient with mPDAC.
RESULTS: With the introduction of NALIRIFOX, 3-year total expenditure was estimated at €24,893,555 compared with €14,093,277 without NALIRIFOX in the market. Market share for NALIRIFOX was projected to increase from 18% in year 1 to 30% in year 3. The inclusion of NALIRIFOX resulted in an average additional cost of €2,387 per patient per year. Across the 3-year horizon, the average annual budget impact was €3,618,093.
CONCLUSIONS: mPDAC is associated with poor prognosis and limited treatment options, creating a high unmet medical need. By improving survival and quality of life, NALIRIFOX represents an important advance for patients and a valuable option for clinicians managing this challenging disease. The introduction of NALIRIFOX provides clinically meaningful benefits with a manageable budget impact for the Greek public payer.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE683
Topic
Economic Evaluation, Health Technology Assessment
Topic Subcategory
Budget Impact Analysis
Disease
Oncology